Literature DB >> 23543655

NR5A1 (SF-1) mutations are not a major cause of primary ovarian insufficiency.

Adela Voican1, Anne Bachelot, Jérôme Bouligand, Bruno Francou, Jérôme Dulon, Marc Lombès, Philippe Touraine, Anne Guiochon-Mantel.   

Abstract

CONTEXT: Primary ovarian insufficiency (POI) is a disorder affecting approximately 1% of women under the age of 40 years. NR5A1 (SF-1) mutations have been recently reported in association with POI.
OBJECTIVE: Our objective was to evaluate the frequency and functional impact of NR5A1 variants in POI. PATIENTS AND METHODS: One hundred eighty patients diagnosed with idiopathic POI were screened for NR5A1 mutations and functional analysis was performed for the identified variants. The DNA-binding capacity of the variants was evaluated by means of EMSA, while their transcriptional activity was assessed using luciferase reporter assays.
RESULTS: Sequencing the NR5A1 gene revealed 4 missense variants in 3 patients. These patients were aged 20, 25, and 33 years at diagnosis and presented with secondary amenorrhea. None of them presented a syndromic form, although 2 had a familial history of POI. The functional analysis carried out for these missense variants showed no significant difference in DNA binding capacity or in transcriptional activity compared to wild-type NR5A1.
CONCLUSIONS: Our study in a large cohort of patients with POI showed the prevalence of NR5A1 mutations to be low (1.6%, upper 95% confidence interval 3.5%). Moreover, no functional impact was observed. Overall, in contrast with the initial report, our results exclude NR5A1 mutations as a major genetic cause of POI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543655     DOI: 10.1210/jc.2012-4111

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  DSDs: genetics, underlying pathologies and psychosexual differentiation.

Authors:  Valerie A Arboleda; David E Sandberg; Eric Vilain
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

2.  Novel NR5A1 missense mutation in premature ovarian failure: detection in han chinese indicates causation in different ethnic groups.

Authors:  Xue Jiao; Yingying Qin; Guangyu Li; Shidou Zhao; Li You; Jinlong Ma; Joe Leigh Simpson; Zi-Jiang Chen
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 3.  DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease.

Authors:  Jenifer P Suntharalingham; Federica Buonocore; Andrew J Duncan; John C Achermann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 4.690

Review 4.  Primary adrenal insufficiency: New genetic causes and their long-term consequences.

Authors:  Federica Buonocore; John C Achermann
Journal:  Clin Endocrinol (Oxf)       Date:  2019-10-30       Impact factor: 3.478

5.  Case Report: Severe Gonadal Dysgenesis Causing 46,XY Disorder of Sex Development Due to a Novel NR5A1 Variant.

Authors:  Kheloud M Alhamoudi; Balgees Alghamdi; Abeer Aljomaiah; Meshael Alswailem; Hindi Al-Hindi; Ali S Alzahrani
Journal:  Front Genet       Date:  2022-07-05       Impact factor: 4.772

6.  NR5A1 gene variants repress the ovarian-specific WNT signaling pathway in 46,XX disorders of sex development patients.

Authors:  Ingrid M Knarston; Gorjana Robevska; Jocelyn A van den Bergen; Stefanie Eggers; Brittany Croft; Jason Yates; Remko Hersmus; Leendert H J Looijenga; Fergus J Cameron; Klaus Monhike; Katie L Ayers; Andrew H Sinclair
Journal:  Hum Mutat       Date:  2018-11-30       Impact factor: 4.878

7.  Analysis of variants in GATA4 and FOG2/ZFPM2 demonstrates benign contribution to 46,XY disorders of sex development.

Authors:  Jocelyn A van den Bergen; Gorjana Robevska; Stefanie Eggers; Stefan Riedl; Sonia R Grover; Philip B Bergman; Chris Kimber; Ashish Jiwane; Sophy Khan; Csilla Krausz; Jamal Raza; Irum Atta; Susan R Davis; Makato Ono; Vincent Harley; Sultana M H Faradz; Andrew H Sinclair; Katie L Ayers
Journal:  Mol Genet Genomic Med       Date:  2020-01-21       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.